Drug makers Exelixis, Inc. (EXEL) and Merck & Co Inc.(MRK) announced Monday that they have entered into a clinical development ...

Alameda, California Tuesday, October 15, 2024, 14:00 Hrs [IST] ...

"Exelixis and MSD to trial cancer therapies together in clinical collaboration" was originally created and published by ...

EXEL is set to evaluate investigational zanzalintinib in combination with Merck;s Keytruda (pembrolizumab) and Welireg in head and neck cancer and renal cell carcinoma, respectively.

Exelixis, an Alameda, Calif., oncology company, and Rahway, N.J., drugmaker Merck said they also plan a Phase 1/2 trial and two Phase 3 studies of zanzalintinib in combination with Merck's Welireg in ...

Lineage Cell Therapeutics, Inc. , a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that Brian M. Culley, Lineage's Chief Executive ...

Patients in England and Wales with a rare genetic disorder will soon be able to access treatment with MSD's Welireg via the NHS, nearly a year after their counterparts in Scotland. In final draft ...

Okta, Inc. , the leading independent Identity partner, today announced that it will webcast the Opening Keynote of Oktane and Investor Summit on October 16, 2024. Each presentation will be webcast ...

On October 14, 2024, MRK announced a clinical development collaboration with Exelixis to evaluate the investigational drug ...

In a report released today, Peter Lawson from Barclays maintained a Hold rating on Exelixis (EXEL – Research Report), with a price target ...

S ean Korbitz was a 20-year-old college student when he first started experiencing symptoms of von Hippel-Lindau syndrome, ...

In the 1990s, China began sending pandas to foreign zoos to be bred, in the hope that future generations could be released into the wild. It hasn’t gone as planned. By Mara Hvistendahl and Joy ...